NCT00856180View on ClinicalTrials.gov

Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

January 31, 2014

Conditions

Ovarian CancerPeritoneal CancerFallopian Tube Cancer

Interventions

DRUG

Bevacizumab

DRUG

Cyclophosphamide

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER